Zentalis - ZNTL Enterprise Value-to-Revenue Multiple

Public company logo of Zentalis (ZNTL)

Zentalis Pharmaceuticals (ZNTL) is scaling cell cycle inhibitors for lung and ovarian therapies. Success in competing with industry behemoths depends on patient survival data. The shift in EV/Sales reflects market expectations, with the indicator reaching 0.00. Simultaneously, the company is implementing strict ESG protocols regarding chemical disposal and laboratory energy efficiency.

ZNTL: Zentalis Pharmaceuticals, Inc. Company Value to Revenue 11/23/2025 - 11/21/2026

ZNTL (Zentalis Pharmaceuticals Inc): analytical breakdowns and indicator data

Fundamental company valuation:ZNTL (zentalis.com)
Mass-produced product of Zentalis Pharmaceuticals, Inc.

The EV/Sales ratio measures the enterprise value of a business, including net debt, relative to sales volume, allowing for the valuation of a single dollar of revenue regardless of financial leverage. Analyzing the EV/Sales trend helps determine the extent of overpayment for Zentalis Pharmaceuticals (ZNTL) assets, which is critical for a biotech center that minimizes capital expenditures through the outsourcing of manufacturing and clinical trials.